- Topics
- Regions
- Events
- Webcasts
- Resources
- CW Exclusives
- Membership
“For tracking litigation, enforcement, and regulatory developments, Compliance Week
should be your prime source.”- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
Was the GlaxoSmithKline FCPA resolution a missed opportunity?
Tom Fox questions whether U.S. regulators missed a chance to illustrate how they would give credit for anti-corruption prosecutions done by other governments in the case of GlaxoSmithKline’s China subsidiary’s recent FCPA resolution.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefFirm, two execs fined, including ex-CCO, for misappropriating $220K, SEC alleges
Two executives at New York-based Momentum Advisors, including the firm’s chief compliance officer, allegedly misappropriated more than $220,000, the Securities and Exchange Commission said.
-
PremiumAs DOJ pivots away from white-collar enforcement, is FCPA still relevant?
While executives and boards will never conclude that bribery is a legitimate way of doing business, understandably many have questions about how to direct their FCPA compliance program efforts and resources, write Iris Bennett and Claire Rajan, partners at law firm Steptoe.
-
PremiumNew era dawns on crypto industry with SEC dismissal of Coinbase case
The Securities and Exchange Commission dismissed its lead case against the cryptocurrency industry, a lawsuit against crypto exchange Coinbase, signaling an about-face in the agency’s enforcement approach toward digital assets under President Donald Trump.